Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

REVEAL is a randomised trial investigating the effects of adding anacetrapib (a potent CETP inhibitor) to effective LDL-lowering treatment with atorvastatin. Over 30,000 participants with pre-existing atherosclerotic vascular disease have been randomised between anacetrapib 100 mg daily versus matching placebo, along with active atorvastatin. Follow-up is scheduled to continue for a median of about 4 years. The primary aim is to assess the effect of anacetrapib on the composite outcome of major coronary event, defined as coronary death, myocardial infarction or coronary revascularization. Secondary aims include assessment of the safety of anacetrapib, as well as the effects on a number of other outcomes.

Recruitment of over 30,000 study participants was completed between 2011 and 2013.

Results published in 2017.

The trial is coordinated at CTSU, with academic collaborators leading regional coordinating centres in Europe, North America and China. The University of Oxford is the trial Sponsor. Financial support has been provided by Merck Sharp & Dohme. Identifier: NCT01252953 

ISRCTN: 48678192

Our team

  • Martin Landray
    Martin Landray

    Professor of Medicine and Epidemiology

  • Louise Bowman
    Louise Bowman

    Professor of Medicine & Clinical Trials, and Honorary Consultant Physician (Lipidology)

  • Rory Collins
    Rory Collins

    Head of Nuffield Department of Population Health and BHF Professor of Medicine and Epidemiology

  • Jemma Hopewell
    Jemma Hopewell

    Professor of Precision Medicine & Epidemiology


Unrestricted grant from Merck, Sharp and Dohne (see Unit's funding policy here)

Related research themes